• Alias: ARQ 197
    • An orally bioavailable small molecule that binds to the MET protein and disrupts MET signal transduction pathways
    • Currently under investigation in phase 3 clinical trial with HCC and in phase 2 clinical trials with many cancer types, including NSCLC, prostate, breast, and head and neck
    • Recommended dose: 240 to 360 mg PO twice daily
    • Half-life: â™2 hours
    • Common side effects: Fatigue, nausea, neutropenia, anemia, asthenia
    (Mekhail et al., 2009; Yap et al., 2011)
    Other topics in Targeted and Immunotherapy Agents